Key statistics
As of last trade Hansa Biopharma AB (24H:DUS) traded at 3.57, -9.06% below its 52-week high of 3.93, set on Feb 12, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 3.73 |
|---|---|
| High | 3.73 |
| Low | 3.57 |
| Bid | 3.45 |
| Offer | 3.48 |
| Previous close | 3.73 |
| Average volume | 645.71 |
|---|---|
| Shares outstanding | 101.76m |
| Free float | 48.58m |
| P/E (TTM) | -- |
| Market cap | 4.07bn SEK |
| EPS (TTM) | -6.44 SEK |
Data delayed at least 15 minutes, as of Feb 16 2026 11:32 GMT.
More ▼
Press releases
- Hansa Biopharma Reports Fourth Quarter and Full-Year 2025 Financial Results
- Hansa Biopharma Reports Fourth Quarter and Full-Year 2025 Financial Results
- Hansa Biopharma has won the 2025 SwedenBIO Award
- Hansa Biopharma has won the 2025 SwedenBIO Award
- Hansa Biopharma Submits BLA to FDA for Imlifidase in desensitization for Kidney Transplantation
- Hansa Biopharma Submits BLA to FDA for Imlifidase in desensitization for Kidney Transplantation
More ▼
